Back
Rocket Pharmaceuticals, Inc. (RCKT)
BiotechnologyRCKT · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$3.77
+6.94%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-2.01
ROE
-64.4%
Gross margin
0.0%
Debt/Equity
0.10x
Revenue growth
P/B ratio
Beta
Forward P/E
Rocket Pharmaceuticals, Inc. — company intelligence
Earnings surprises
Q2 2026$-0.15 vs $0.25 est-160.8%
Q1 2026$-0.42 vs $-0.42 est-1.2%
Q4 2025$-0.38 vs $-0.46 est+17.8%
Q3 2025$-0.45 vs $-0.52 est+12.6%
Insider activity · 90 days
14 buys2 sellsnet +678,784 shares
Stevens Christopher JamesSell 36,658 · Aug 11, 2026
Chaudhuri SarbaniSell 4,701 · Aug 11, 2026
Stevens Christopher JamesBuy 73,313 · Aug 3, 2026
Recent SEC filings
4 — Insider transaction reportAug 20, 2026
4 — Insider transaction reportAug 20, 2026
4 — Insider transaction reportAug 17, 2026
Latest news
Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy' — SeekingAlpha · 1w ago
Wedbush Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $15 — Benzinga · 2w ago
Rocket Pharmaceuticals Q2 Adj. EPS $(0.37) Misses $0.24 Estimate — Benzinga · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.